PROVENGE (sipuleucel-T)
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
ApprovedActive
Key Facts
Indication
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase
Approved
Status
Active
Company
About Dendreon
Dendreon is a trailblazer in the cell therapy space, having achieved the historic first FDA approval of an autologous cellular immunotherapy, Provenge, for advanced prostate cancer in 2010. The company has leveraged its deep expertise in complex, personalized cell therapy manufacturing and commercialization to build a dual-pillar business model: marketing Provenge and providing end-to-end manufacturing services as a CDMO for partners. While facing past financial challenges, Dendreon's current strategy focuses on expanding the reach of its proven therapy and capitalizing on the booming cell and gene therapy market through its specialized manufacturing capabilities.
View full company profileTherapeutic Areas
Other Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Tomivosertib | eFFECTOR Therapeutics | Phase 2 |
| Gedatolisib + Darolutamide | Celcuity | Phase 1b/3 |
| SNP-101 (estimated) | SmartNuclide Biopharma | Phase 1 |
| AB001 (²¹²Pb-NG001) | ARTBIO | Phase 1/2 |
| AB-3028 | Arsenal Biosciences | IND-Enabling |
| PRO CAR-201A | PromiCell | Phase 1 |
| PRO CAR-202 | PromiCell | Preclinical |
| FG-3246 | Kyntra Bio | Phase 2 |
| RP12146 | Rhizen Pharmaceuticals | Phase 1b |
| Monoclonal Antibody (undisclosed) | MetaCurUm Biotech | Preclinical |
| ModraDoc006/r | Modra Pharmaceuticals | Phase 2b |
| SYNC-T | Syncromune | Phase 2 |